Lista de obras -

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

artículo científico publicado en 2020

<i>STAT3</i> and <i>STAT5B</i> Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features

scientific article published on 25 November 2020

A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

artículo científico publicado en 2019

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

artículo científico publicado en 2016

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

artículo científico publicado en 2017

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

artículo científico publicado en 2009

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

artículo científico publicado en 2015

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

artículo científico publicado en 2020

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

artículo científico publicado en 2020

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

artículo científico publicado en 2017

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

artículo científico publicado en 2017

Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

artículo científico publicado en 2014

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

artículo científico publicado en 2018

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

artículo científico publicado en 2013

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

artículo científico publicado en 2018

Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

artículo científico publicado en 2019

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis

artículo científico publicado en 2017

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

artículo científico publicado en 2013

Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

artículo científico publicado en 2020

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

artículo científico publicado en 2015

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

artículo científico publicado en 2020

Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas

scientific article published on 17 June 2019

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

artículo científico publicado en 2012

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

artículo científico publicado en 2016

Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

artículo científico publicado en 2012

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

artículo científico publicado en 2020

Origin of Waldenstrom's macroglobulinaemia

artículo científico publicado en 2016

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

artículo científico publicado en 2020

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

artículo científico publicado en 2016

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

artículo científico publicado en 2016

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

artículo científico publicado en 2019

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

artículo científico publicado en 2016

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

artículo científico publicado en 2014

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

artículo científico publicado en 2017

Reply to Brown et al: 'Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis'

artículo científico publicado en 2019

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

scientific article published on 22 April 2019

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

scientific article published on 23 October 2015

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

article

Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation

artículo científico publicado en 2010

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

artículo científico publicado en 2015

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.

artículo científico publicado en 2016

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

artículo científico publicado en 2014

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

artículo científico publicado en 2012

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.

artículo científico publicado en 2018

Lista de obras de

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

<i>STAT3</i> and <i>STAT5B</i> Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features

A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Origin of Waldenstrom's macroglobulinaemia

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

Reply to Brown et al: 'Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis'

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.